Mar 5, 2026 4:01 pm EST Evommune Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights
Feb 10, 2026 7:30 am EST Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic Dermatitis
Dec 11, 2025 4:05 pm EST Evommune Reports Third Quarter 2025 Financial Results and Provides Business Update
Nov 7, 2025 4:05 pm EST Evommune Announces Closing of its Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
Sep 19, 2025 8:30 am EDT Evommune Presents Full Phase 2 Data for Oral MRGPRX2 Inhibitor EVO756 in Chronic Inducible Urticaria During Late-Breaker at EADV 2025 Congress
Sep 2, 2025 9:30 am EDT Evommune Announces Late-Breaker Presentation of Phase 2 Data for EVO756 in Chronic Inducible Urticaria at Upcoming European Academy of Dermatology and Venereology (EADV) 2025 Congress
